CClinicalTrials.gg
CompletedNCT07153822Updated Sep 22, 2025

Efficacy and Safety of Ionized Atelocollagen Adhesion Barrier (Collabarrier®) in Spine Surgery

An interventional study of Collagen-based adhesion barrier and Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier in Lumbar Spinal Stenosis, Lumbar Disc Herniation and Epidural Fibrosis, sponsored by DALIM TISSEN Co., Ltd.. Completed at 6 sites in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.

Sponsored by DALIM TISSEN Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Dec 2022, registered Aug 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Study summary

This multicenter, randomized, subject- and evaluator-blinded, active-controlled, non-inferiority clinical trial was conducted to evaluate the efficacy and safety of Collabarrier®, a collagen-based adhesion barrier, compared to Guardix-sol in patients undergoing lumbar spine surgery for herniated disc or spinal stenosis.

A total of 69 adult patients scheduled for first-time partial laminectomy or discectomy were enrolled and randomly assigned to receive either Collabarrier® or Guardix-sol. The investigational device (Collabarrier®) is a gel-type atelocollagen formulation designed to prevent postoperative adhesions by acting as a physical barrier between the dura mater and surrounding tissues.

The primary outcome was the mean MRI Scar Score at 6 weeks postoperatively, assessed by independent evaluators blinded to treatment allocation. Secondary outcomes included patient-reported pain scores using a 100-mm Visual Analog Scale (VAS) for low back and leg pain, and functional limitation assessed using the Oswestry Disability Index (ODI), measured at baseline, 3 weeks, and 6 weeks.

02

Conditions studied

  • Lumbar Spinal Stenosis
  • Lumbar Disc Herniation
  • Epidural Fibrosis
  • Postoperative Adhesion
03

In context

Spinal Stenosis

459 studies on the registry are indexed under Spinal Stenosis; 103 are open to participants now.

This study's enrollment of 69 is below the median of 80 across 283 interventional studies indexed under Spinal Stenosis.

Browse Spinal Stenosis studies →

Lead sponsor

DALIM TISSEN Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male or female participants aged 19 years or older
  • Patients diagnosed with lumbar disc herniation or lumbar spinal stenosis based on radiological evidence (MRI or CT) showing nerve root compression at one of the following single levels: L3-L4, L4-L5, or L5-S1
  • Patients scheduled to undergo their first partial laminectomy or discectomy for the above condition
  • Patients who meet at least one of the following criteria (A, B, C):
  • A. Have undergone a minimum of 4 weeks of prior conservative treatment within the 6 months prior to Visit 1 (e.g., physical therapy, use of anti-inflammatory drugs, or muscle relaxants)
  • B. Experience intolerable pain and are judged by the investigator to require surgery for lumbar disc herniation or spinal stenosis
  • C. Have significant progression of neurological functional loss
  • Patients who voluntarily provide written informed consent and are able to comply with the study procedures and visit schedule

Exclusion criteria

Exclusion Criteria:

  • Patients who shows alergic reaction or has previous stroke to main and other ingredients or components of the medical device for this clinical test
  • Patients with a medical history of brittle bone
  • Patients with a medical history of fracture in lumbar region or ligament injuries by external injury
  • Patients who needs to undergo a spine surgery (osteotomy allowable) in addition to partial laminectomy or percutaneous lumbar discectomy for cure of symptom
  • Patients with neurological function disorder on intestine/bladder
  • Patients with any of such symptoms as excessive exudation, bleeding, acute edema and infection on the part applied
  • Patients with Degenerative spinal disorder (other than disc herniation or spinal stenosis) or scoliosis (Cobb's angle is 15° or bigger)
  • Patients with any of lymphatic disease, coagulation disoder and/or coagulant taken
  • Patients with uncontrolled diabetes that may affect the surgery or the progress after surgery based on the tester's judgment
  • Patients with desmosis or autoimmune disease or who has ever taken malignant tumor treatment within 5 years before this surgery
  • Patients who has ever undergone a spine surgery on the part for this surgery
  • Patients who has ever taken extradural steroid treatment within 2 weeks before surgery or oral steroid drug within 10 days before surgery
  • Patients who has ever taken myelogram or lumbar puncture within 24 hours before screening
  • Patients with impaired immunity or clinically significant abnormalities in clinical laboratory tests at screening Patients with immunity deteriorated or who shows clinically significant abnormality in lab test items at the moment of screening
  • Patients who present clinically severe impairment in cardiovascular, digestive, respiratory, endocrine, or central nervous system, or have a mental illness that significantly affects the trial
  • Participated in other clinical trials within 30 days from the screening
  • A pregnant woman or lactating woman
  • Patients who cannot comply with any requirement of the document form consent for this clinical test from the signing date of signature on the consent till the final day of visit
  • Patients determined by the researcher to be non-conformable to this clinical trials.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Collabarrier®

    Device: Collagen-based adhesion barrier

  • Active comparator
    Guardix-sol

    Device: Sodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier

Interventions

  • DeviceCollagen-based adhesion barrier

    Porcine Atelocollagen (Type I)

    Also known as: adhesion barrier

  • DeviceSodium hyaluronate(HA) and Sodium Carboxymethylcellulose(CMC)-based adhesion barrier

    Sodium Hyaluronate(HA) + Sodium Carboxymethylcellulose(CMC)

    Also known as: adhesion barrier

06

What researchers measure

Primary outcomes

  1. Mean value of MRI scar score assessed by independent evalutor at 6 weeks after medical device use for clinical trial

    Time frame: 6 weeks after medical device application

Secondary outcomes

  1. Mean value of 100-mm Visual Analogue Scale (VAS) for back pain assessed by the subject before and at 3 and 6 weeks after medical device use for clinical trial

    Time frame: Baseline, 3 weeks, and 6 weeks after medical device application

  2. Mean value of 100-mm Visual Analogue Scale (VAS) for leg pain assessed by the subject before and at 3 and 6 weeks after medical device use for clinical trial

    Time frame: Baseline, 3 weeks, and 6 weeks after medical device application

  3. Mean value of Oswestry Disability Index (ODI) for limitations of daily life assessed by the subject before and at 3 and 6 weeks after medical device use for clinical trial

    Time frame: Baseline, 3 weeks, and 6 weeks after medical device application

07

Study locations

6 sites
  • Ajou University Hospital
    Seoul, South Korea
  • Asan Medical Center
    Seoul, South Korea
  • Korea University Anam Hospital
    Seoul, South Korea
  • The Catholic University of Korea Eunpyeong St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea Seoul St. Mary's Hospital
    Seoul, South Korea
  • The Catholic University of Korea St. Vincent's Hospital
    Seoul, South Korea
08

References and documents

Individual participant data

Plan to share: Undecided — The sponsor has not yet determined whether individual participant data (IPD) will be shared.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153822
Lead sponsor
DALIM TISSEN Co., Ltd.
Responsible party
Sponsor
First posted
Sep 4, 2025
Start date
Dec 15, 2022
Primary completion
Jan 29, 2024
Completion
Jan 29, 2024
Last update
Sep 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion